CN110352190A - 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物 - Google Patents

用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物 Download PDF

Info

Publication number
CN110352190A
CN110352190A CN201780077202.8A CN201780077202A CN110352190A CN 110352190 A CN110352190 A CN 110352190A CN 201780077202 A CN201780077202 A CN 201780077202A CN 110352190 A CN110352190 A CN 110352190A
Authority
CN
China
Prior art keywords
compound
cancer
alkyl
independently
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780077202.8A
Other languages
English (en)
Chinese (zh)
Inventor
布莱恩·T·奥兰斯基
简·西金斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Episinte Trex Co
Original Assignee
Episinte Trex Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Episinte Trex Co filed Critical Episinte Trex Co
Publication of CN110352190A publication Critical patent/CN110352190A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780077202.8A 2016-10-14 2017-10-13 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物 Pending CN110352190A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408182P 2016-10-14 2016-10-14
US62/408,182 2016-10-14
PCT/US2017/056454 WO2018071741A1 (en) 2016-10-14 2017-10-13 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine

Publications (1)

Publication Number Publication Date
CN110352190A true CN110352190A (zh) 2019-10-18

Family

ID=61906413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780077202.8A Pending CN110352190A (zh) 2016-10-14 2017-10-13 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物

Country Status (13)

Country Link
US (1) US11008287B2 (OSRAM)
EP (1) EP3526195A4 (OSRAM)
JP (1) JP7332469B2 (OSRAM)
KR (1) KR20190128619A (OSRAM)
CN (1) CN110352190A (OSRAM)
AU (2) AU2017342436C1 (OSRAM)
BR (1) BR112019007453A2 (OSRAM)
CA (1) CA3040479A1 (OSRAM)
EA (1) EA201990949A1 (OSRAM)
IL (1) IL265970B (OSRAM)
MX (1) MX2019004280A (OSRAM)
SG (1) SG11201903312VA (OSRAM)
WO (1) WO2018071741A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
EA201891606A1 (ru) 2016-01-11 2019-02-28 Эписентарикс, Инк. Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
JP7332469B2 (ja) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
EP4355320A4 (en) * 2021-06-16 2025-07-30 Epicentrx Inc ORGANONITRO AND SULFOXYALKYL COMPOUNDS USED IN THE TREATMENT OF MEDICAL DISORDERS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370492A (zh) * 2005-08-12 2009-02-18 阿利安特技术系统股份有限公司 环状硝基化合物及其药物组合物和用途
US20130053418A1 (en) * 2011-08-26 2013-02-28 Jan Scicinski Acyclic organonitro compounds for use in treating cancer
WO2013052164A1 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (ja) 1990-11-13 1997-09-30 株式会社日立製作所 表示制御装置
TW198712B (OSRAM) * 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE69226197T2 (de) 1991-11-08 1999-02-11 Somatogen, Inc., Boulder Hämoglobine als arzneimittelabgabesystem
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
PT1051972E (pt) 1994-05-27 2007-12-07 Strakan Internat Ltd Uma Socie Composição dadora de óxido nítrico para tratamento de distúrbios anais
DK0814861T3 (da) 1995-03-14 2002-10-07 Siemens Ag Udskiftelig præcisionsdoseringsenhed til ultralydforstøveranordning
EP0814860B1 (en) 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
WO1996036602A1 (en) 1995-05-15 1996-11-21 The United States Of America Adnaz, compositions and processes
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
IL128589A0 (en) 1996-10-15 2000-01-31 Eastman Chem Co Explosive formulations
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
CA2337690C (en) 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
CZ20023213A3 (cs) 2000-04-10 2003-12-17 Pfizer Products Inc. Benzoamidové piperidinové sloučeniny a příbuzné sloučeniny
US6861530B2 (en) 2000-07-07 2005-03-01 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
DE10111049A1 (de) 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2004004648A2 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2004032864A2 (en) 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2004098538A2 (en) 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
ES2358801T3 (es) 2003-06-25 2011-05-13 Je Il Pharmaceutical Co., Ltd. Derivados tricíclicos o sales farmacéuticamente aceptables de los mismos, sus preparaciones y composiciones farmacéuticas que los contienen.
AU2004255268B2 (en) 2003-07-09 2010-04-01 Loma Linda University Use of nitrite salts for the treatment of cardiovascular conditions
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
CA2579096C (en) 2004-09-08 2012-11-13 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds
AU2006228957A1 (en) 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US20120149678A1 (en) 2010-12-09 2012-06-14 Oronsky Bryan T Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
EA201891606A1 (ru) 2016-01-11 2019-02-28 Эписентарикс, Инк. Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
JP7332469B2 (ja) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370492A (zh) * 2005-08-12 2009-02-18 阿利安特技术系统股份有限公司 环状硝基化合物及其药物组合物和用途
US20130053418A1 (en) * 2011-08-26 2013-02-28 Jan Scicinski Acyclic organonitro compounds for use in treating cancer
WO2013052164A1 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
SCICINNSKI J.等: "Preclinical evaluation of the metabolism and disposition of RRx-001，a novel investigative anticancer agent", 《DRUG METABOLISM AND DISPOSITION》 *
SCICINSKI J.等: "Development of methods for the bioanalysis of RRx-001 and metabolites", 《BIOANALYSIS》 *
尤启冬 主编: "《药物化学》", 28 February 2011 *
左伋 等主编: "《医学细胞生物学》", 30 June 2015 *
贾娴: "《国家执业药师资格考试药物化学过关全攻略》", 31 March 2008 *

Also Published As

Publication number Publication date
AU2022203169B2 (en) 2024-04-18
SG11201903312VA (en) 2019-05-30
AU2022203169A1 (en) 2022-06-02
EP3526195A1 (en) 2019-08-21
IL265970B (en) 2022-03-01
KR20190128619A (ko) 2019-11-18
AU2017342436C1 (en) 2022-11-03
BR112019007453A2 (pt) 2019-07-16
AU2017342436A1 (en) 2019-05-02
CA3040479A1 (en) 2018-04-19
EA201990949A1 (ru) 2019-10-31
AU2017342436B2 (en) 2022-05-19
EP3526195A4 (en) 2020-05-20
JP7332469B2 (ja) 2023-08-23
JP2019532067A (ja) 2019-11-07
MX2019004280A (es) 2019-09-18
US20200157047A1 (en) 2020-05-21
WO2018071741A1 (en) 2018-04-19
US11008287B2 (en) 2021-05-18
WO2018071741A8 (en) 2019-05-31
IL265970A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
CN110352190A (zh) 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物
JP6019126B2 (ja) 有機ニトロチオエーテル化合物およびその医療用途
CN101583606B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
TWI389895B (zh) 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
TW202144340A (zh) 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
AU2012333986B2 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US9637484B2 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
US20110112135A1 (en) Imidazo [1,2-A] Pyridine Compounds
KR20070006891A (ko) 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
JP2010521527A5 (OSRAM)
JP2012508250A (ja) キノキサリン系のｌｘｒモジュレーター
AU2018359224B2 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
US12297193B2 (en) PTPN2/PTP1B degrader and therapeutic method thereof
JP2008520644A (ja) オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
WO2025051180A1 (zh) 内酰胺类衍生物及其应用
WO2025240834A1 (en) Nsd2-targeted chemical degraders and compositions and methods of use thereof
CN108409729A (zh) 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination